Wohl, D A <br/><br/>
The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.  [electronic resource] 

 -  HIV medicine  Feb 2016 
 - 106-17 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1468-1293 
<br/><br/><label>Standard No.: </label>10.1111/hiv.12281  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Anti-HIV Agents--therapeutic use<br/>Antiretroviral Therapy, Highly Active<br/>Atazanavir Sulfate--therapeutic use<br/>Biomarkers--blood<br/>Bone Density--drug effects<br/>CD4 Lymphocyte Count<br/>Dideoxynucleosides--therapeutic use<br/>Drug Combinations<br/>Drug Substitution--methods<br/>Female<br/>HIV Infections--blood<br/>Humans<br/>Kidney--drug effects<br/>Lamivudine--therapeutic use<br/>Lipids--blood<br/>Male<br/>Middle Aged<br/>RNA, Viral--blood<br/>Ritonavir--adverse effects<br/>Treatment Outcome<br/>Viral Load